Significant Ownership of Ikarian Capital, LLC

Large-stake snapshot 1 signal
Large-stake filing summary
  • Recent SEC Schedule 13D/G filings for Ikarian Capital, LLC focus on large-stake beneficial ownership disclosures and amendments.
  • Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
Manager Names, identifiers, and filing context for this profile. 2 identity fields
Manager signature
/s/ Neil Shahrestani - Neil Shahrestani, Sole Manager
Manager location
Dallas, TX

Follow Filing Activity

Follow Ikarian Capital, LLC with Pro and return when a new Schedule 13D/G filing changes the record on this page.

Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.

Review Pro alert access Already have an account? Sign in and return here

Significant Ownership of Ikarian Capital, LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
QNRX Quoin Pharmaceuticals, Ltd. American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share 13% $3,052,472 211,538 0% Ikarian Capital, LLC 31 Jan 2026
SPRB Spruce Biosciences Inc. Common Stock, par value $0.0001 per share 11% $1,060,227 121,356 0% Ikarian Capital, LLC 31 Oct 2025
NXTC NextCure, Inc. Common Stock, $0.001 par value per share 10% $4,715,825 363,035 Ikarian Capital, LLC 31 Dec 2025
TRAW Traws Pharma, Inc. Common stock, par value $.01 per share 10% $1,308,164 +$359,065 812,524 +38% Ikarian Capital, LLC 31 Dec 2025
GRTX Galera Therapeutics, Inc. Common Stock, $0.001 par value per share 10% $376,934 7,538,690 Ikarian Capital, LLC 31 Dec 2024
CNTB Connect Biopharma Holdings Limited Ordinary Shares, par value $0.000174 per Share 8.8% $13,910,809 4,933,086 Ikarian Capital, LLC 31 Dec 2025
PTHS Pelthos Therapeutics Inc. Common Stock, par value $0.0001 per share 7.7% $5,901,754 +$19,320 256,598 +0.33% Ikarian Capital, LLC 31 Mar 2026
CHRO Channel Therapeutics Corp Common Stock, par value $0.0001 per share 7.3% $564,287 440,849 Ikarian Capital, LLC 31 Dec 2024
TENX Tenax Therapeutics, Inc. Common Stock, $0.0001 par value per share 6.7% $13,077,042 +$2,027,050 1,145,100 +18% Ikarian Capital, LLC 31 Mar 2026
LPCN Lipocine Inc. Common Stock, par value $0.0001 per share 6.3% $1,062,882 508,556 Ikarian Capital, LLC 31 Mar 2026
CNSP CNS Pharmaceuticals, Inc. Common Stock 5.7% $118,700 45,830 Ikarian Capital, LLC 31 Dec 2025
KZIA Kazia Therapeutics Limited American Depositary Shares, each representing five-hundred Ordinary Shares 5.1% $3,740,056 580,754 Ikarian Capital, LLC 31 Dec 2025
FBRX Forte Biosciences, Inc. Common Stock, $0.001 par value 5% $6,516,387 +$89,063 617,667 +1.4% Ikarian Capital, LLC 30 Jun 2025
IBIO IBIO, Inc. Common Stock 5% $947,430 1,151,051 Ikarian Capital, LLC 30 Sep 2025
ACOG Alpha Cognition Inc. Common Shares, no par value 4.9% $6,865,684 +$574,548 1,056,259 +9.1% Ikarian Capital, LLC 31 Dec 2025
CPIX Cumberland Pharmaceuticals Inc. Common Stock, no par value 4.9% $3,545,020 730,932 Ikarian Capital, LLC 31 Mar 2025
RLMD Relmada Therapeutics, Inc. Common Stock, par value $0.001 par value per share 4.8% $7,122,152 3,543,359 Ikarian Capital, LLC 30 Sep 2025
SPRB Spruce Biosciences Inc. Common Stock, par value $0.0001 per share 4.8% $8,495 121,356 Ikarian Capital, LLC 30 Apr 2026
GCTK Glucotrack, Inc. Common Stock, par value $0.001 per share 4.5% $175,071 45,830 Ikarian Capital, LLC 31 Dec 2025
ATXI Avenue Therapeutics, Inc. Common Stock 4.1% $86,341 -$6,059 130,820 -6.6% Ikarian Capital, LLC 31 Dec 2025
AVTX Avalo Therapeutics, Inc. Common Stock, $0.001 Par Value 3.8% $9,049,101 -$6,100,673 711,967 -40% Ikarian Capital, LLC 30 Sep 2025
AEMD Aethlon Medical, Inc. Common Stock, $0.001 par value per share 2% $5,685 -$449,150 15,366 -99% Ikarian Capital, LLC 30 Sep 2025
GLTO Galecto, Inc. Common Stock, $0.00001 par value per share 0.6% 335,710 +18% Ikarian Capital, LLC 28 Feb 2026
KPTI Karyopharm Therapeutics Inc. Common Stock, par value $0.0001 per share 0% $0 0 Ikarian Capital, LLC 31 Mar 2026

Schedules 13D/G Reported by Ikarian Capital, LLC:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .